title: Long-term efficacy of rasagiline in early Parkinson's disease.
abstract: This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 +/- 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25% of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.
authors.affiliation: Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California 90033, USA. mlew@surgery.usc.edu
authors.forename: Mark F
authors.initials: MF
authors.lastname: Lew
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hauser
authors.forename: Howard I
authors.initials: HI
authors.lastname: Hurtig
authors.forename: William G
authors.initials: WG
authors.lastname: Ondo
authors.forename: Joanne
authors.initials: J
authors.lastname: Wojcieszek
authors.forename: Tamar
authors.initials: T
authors.lastname: Goren
authors.forename: Cheryl J
authors.initials: CJ
authors.lastname: Fitzer-Attas
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D018450:Disease Progression; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018491:Dopamine Agonists; D007189:Indans; C031967:rasagiline; D007980:Levodopa